When publishing with Neuroscience and Neuroeconomics you can freely upload supplementary data and video files.
I request you to submit your next manuscript with us and publish it in full under the open access model. You will find our online submission steps quick and easy. Read my call for papers and submit your next paper with us: http://www.dovepress.com/nnpnan.t56560466
An international, peer-reviewed, open access journal focusing on the identification of brain structures and measurement of neural activity related to behaviour, behavioural predictions, and decision making in health and disease.
Dove journals for rigorous, actionable, and constructive peer-review.
6th Annual Symposium of Drug Delivery Systems-2016 Invitation
Dear Dr. Anand Srivastava,
We are extremely proud to announce SDDS-2016. The 6th Annual Symposium of Drug Delivery Systems (SDDS-2016) will go to Nanjing, China. It will be held on November 16-19, 2016 with the theme of Smart Precise Medicine. For your outstanding achievements and experience, we hope you can give a speech at SDDS: Drug Delivery Systems at SDDS-2016. SDDS-2016 is to pave the way for future research challenges and will serve as a platform to exchange new research, ideas and to discuss developments, applications and business prospects in all areas of Drug Delivery and Nanomedicine. It plans to shoot for 200+ oral presentations by the leading scientists in the fields of Drug Delivery and Nanomedicine. We would highly appreciate your presence in the meeting as an expert of the field, please reply and send your speech title to us ASAP. Online Registration is available now.
For the potential Scientific Program, please visit http://www.bitcongress.com/sdds2016/ScientificProgram.aspWe look forward to meeting you in Nanjing!Sincerely yours, Ms. Grace ChenProgram Coordinator East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan,
When it comes to stem cell therapy, it could be an eternity.
That’s why GIOSTAR of San Diego is pushing the stem cell research community to act more aggressively to overcome politics and red tape. It is delaying and preventing the United States from taking the lead in the therapeutic applications. “If America is not working aggressively, we will lose out to Asia”, contends Deven Patel, president, CEO and co-founder of the Global Institute of Stem Cell Therapy and Research (GIOSTAR) of La Jolla, California.
Countries like China, Thailand and India have expedited the process of clinical trials required by the United States and forge ahead into treating degenerative diseases, for which stem cell research holds much promise. Biotechnology is growing so fast in China, that within the next decade, it is expected to comprise 60 percent of that country’s growth! Thailand, another center of therapeutic applications, is the one of the few places in the world — Bangkok Hospital — where stem cell therapy has been developed commercially to tackle congestive heart failure.
“If we are going to take too much time, these countries will take the lead,” Deven Patel added – an irony since it has been the United States, the Salk Research Institute, UCSD, UCI, UCLA, Sanford-Bernham and scientists like GIOSTAR’s Chairman and Co-founder Dr. Anand Srivastava who has been associated with these leading universities and research institutions have pioneered the research for more than dozen years and published extensively in revered scientific journals. Dr. Anand Srivastava has an extensive research experience in the field of adult and Embryonic Stem (ES) cell, which is documented by several publications in revered scientific journals. Dr. Anand Srivastava’s expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Based on his extraordinary scientific achievements his biography has been included in “WHO IS WHO IN AMERICA” data bank two times, first in 2005 and second in 2010.
Dr. Srivastava says, “While stem cell therapy is on the verge of revolution in parts of Asia, it is still regarded in some U.S. medical circles as risky and under the process of development, principally because of the association with ES cells, whose use has led to a high incidence of tumors and carcinoma”. But research has advanced so much in recent years, that ES cells research has been complemented with the use of induced pluripotent cells (iPSC), Dr. Srivastava added. iPSCs are derived from reprogramming a mature adult cell to give it back the properties of an embryonic stem cell. In order for this adult cell to return to a state of immaturity and be able to differentiate into all cell types. Dr. Srivastava says “the beauty of this science is that clinicians do not need to match the cells for transplant because iPSCs can be generated from a patient own cells, who is seeking for medical treatment”.
